Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Current Assets (2020 - 2025)

Historic Current Assets for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to $78.5 million.

  • Inhibikase Therapeutics' Current Assets rose 177433.65% to $78.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.5 million, marking a year-over-year increase of 177433.65%. This contributed to the annual value of $98.5 million for FY2024, which is 59278.01% up from last year.
  • As of Q3 2025, Inhibikase Therapeutics' Current Assets stood at $78.5 million, which was up 177433.65% from $88.8 million recorded in Q2 2025.
  • Inhibikase Therapeutics' 5-year Current Assets high stood at $98.5 million for Q4 2024, and its period low was $4.2 million during Q3 2024.
  • Moreover, its 5-year median value for Current Assets was $26.0 million (2022), whereas its average is $37.8 million.
  • As far as peak fluctuations go, Inhibikase Therapeutics' Current Assets plummeted by 7612.57% in 2024, and later skyrocketed by 177433.65% in 2025.
  • Quarter analysis of 5 years shows Inhibikase Therapeutics' Current Assets stood at $42.5 million in 2021, then plummeted by 42.62% to $24.4 million in 2022, then plummeted by 41.69% to $14.2 million in 2023, then skyrocketed by 592.78% to $98.5 million in 2024, then dropped by 20.23% to $78.5 million in 2025.
  • Its Current Assets stands at $78.5 million for Q3 2025, versus $88.8 million for Q2 2025 and $94.2 million for Q1 2025.